Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial

Tallal Younis; Chris Skedgel

doi:10.2165/11588350-000000000-00000

Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial

Tallal Younis
, Chris Skedgel

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	361-365
Number of pages	5
Journal	PharmacoEconomics
Volume	29
Issue number	5
DOIs	https://doi.org/10.2165/11588350-000000000-00000
Publication status	Published - 2011
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cost-effectiveness
Cost-utility
Early-breast-cancer treatment
Trastuzumab therapeutic use

ASJC Scopus subject areas

Pharmacology
Health Policy
Public Health, Environmental and Occupational Health

Access to Document

10.2165/11588350-000000000-00000

Cite this

@article{9aa8366bfe874f37918a2a644aac174d,

title = "Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial",

keywords = "Cost-effectiveness, Cost-utility, Early-breast-cancer treatment, Trastuzumab therapeutic use",

author = "Tallal Younis and Chris Skedgel",

year = "2011",

doi = "10.2165/11588350-000000000-00000",

language = "English",

volume = "29",

pages = "361--365",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis",

number = "5",

}

TY - JOUR

T1 - Adjuvant trastuzumab for breast cancer

T2 - Uncertainties in clinical and economic evidence following early stopping of the HERA trial

AU - Younis, Tallal

AU - Skedgel, Chris

PY - 2011

Y1 - 2011

KW - Cost-effectiveness

KW - Cost-utility

KW - Early-breast-cancer treatment

KW - Trastuzumab therapeutic use

UR - https://www.scopus.com/pages/publications/79955052041

UR - https://www.scopus.com/pages/publications/79955052041#tab=citedBy

U2 - 10.2165/11588350-000000000-00000

DO - 10.2165/11588350-000000000-00000

M3 - Comment/debate

C2 - 21504237

AN - SCOPUS:79955052041

SN - 1170-7690

VL - 29

SP - 361

EP - 365

JO - PharmacoEconomics

JF - PharmacoEconomics

IS - 5

ER -

Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this